Overview

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) and preliminary antitumor activity of ORIC-944 in patients with metastatic prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
ORIC Pharmaceuticals